Bifidobacterium animalis subsp. lactis

PreclinicalBiologic

Bifidobacterium animalis subsp. lactis is one of 12 biologic programs targeting Hyperbilirubinemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaNot yet recruiting

HyperbilirubinemiaPreclinical

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Hyperbilirubinemia

#DrugCompanyPhaseTrials

Verazinc

FFakultas Kedokteran Universitas Indonesia

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Tricor

JJagotec

Preclinical

2 4

Legalon

BBukwang Pharmaceutical

Preclinical

1 5

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

—7

Glutathione

UUniversity of Chicago

Preclinical

1 8

E. Coli Endotoxin

RRadboud University Medical Center

Preclinical

1 9

Bifidobacterium animalis subsp. lactis

UUniversity of Sao Paulo

Preclinical

1 10

Ademetionine 1,4-Butanedisulfonate

CChina National Center for Cardiovascular Diseases

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalNot yet recruiting

Hyperbilirubinemia

NCT07773012

Clinical

Trials by Indication[1]

Mucositis1 trial

Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis

Completed·UUniversity of Sao Paulo·Phase 3·NCT04187222·38 enrolled

Oral Lichen Planus1 trial

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

Completed·UUniversity of Sao Paulo·Phase 2·NCT03386643·22 enrolled

Hyperbilirubinemia1 trial

Efficacy of Bifidobacterium Animalis Subsp. Lactis as an Adjunct to Phototherapy in the Treatment of Indirect Hyperbilirubinemia in Term Neonates

Not yet recruiting·CCan Tho University of Medicine and Pharmacy·Preclinical·NCT07773012·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bifidobacterium animalis subsp. lactis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bifidobacterium animalis subsp. lactis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bifidobacterium animalis subsp. lactis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Sao Paulo

Bifidobacterium animalis subsp. lactis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Mucositis1 trial

Oral Lichen Planus1 trial

Hyperbilirubinemia1 trial

References

Drug Info

Quick Facts

Related News